Shares of Exscientia plc (NASDAQ:EXAI - Get Free Report) dropped 4.2% during trading on Tuesday . The company traded as low as $5.75 and last traded at $5.75. Approximately 122,599 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 634,453 shares. The stock had previously closed at $6.00.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the company. TD Cowen reiterated a "hold" rating on shares of Exscientia in a research report on Friday, August 9th. Barclays reaffirmed an "equal weight" rating and issued a $5.00 target price on shares of Exscientia in a research report on Tuesday, August 13th.
Get Our Latest Report on Exscientia
Exscientia Trading Down 3.2 %
The firm's 50-day simple moving average is $5.30 and its 200 day simple moving average is $5.38. The stock has a market cap of $702.35 million, a P/E ratio of -4.44 and a beta of 0.85. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.05.
Exscientia (NASDAQ:EXAI - Get Free Report) last posted its earnings results on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.05). Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. The business had revenue of $5.60 million during the quarter. As a group, equities research analysts anticipate that Exscientia plc will post -1.12 earnings per share for the current year.
Institutional Investors Weigh In On Exscientia
A number of hedge funds and other institutional investors have recently modified their holdings of EXAI. GAMMA Investing LLC increased its stake in Exscientia by 112.1% during the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company's stock valued at $25,000 after buying an additional 2,302 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Exscientia by 76.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company's stock worth $53,000 after purchasing an additional 4,029 shares in the last quarter. EntryPoint Capital LLC lifted its position in Exscientia by 22.8% in the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company's stock worth $178,000 after purchasing an additional 5,784 shares during the period. Walled Lake Planning & Wealth Management LLC acquired a new stake in Exscientia in the fourth quarter worth approximately $64,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Exscientia during the 2nd quarter valued at $54,000. 41.58% of the stock is currently owned by institutional investors.
Exscientia Company Profile
(
Get Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
See Also
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
